Alpha-Fetoprotein : Its Diagnostic Role in Hepatocellular Carcinoma
),
(1) Division of Gastroenterology and Hepatology Department of Internal Medicine Dr. Sardjito General Hospital / Faculty of Medicine, Public Health & Nursing, Universitas Gadjah Mada, Yogyakarta Indonesia
Corresponding Author
Abstract
References
Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hie-Won H. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of hepatocellular carcinoma in patients after tumor ablation and with low AFP level. Viruses. 2022;14(4):775. doi:10.3390/v14040775.
Snowberger N, Chinnakotla S, Lepe RM, Peattie J, Goldstein R, Klintmalm GB, Davis GL. Alpha-fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther. 2007;26(9):1187-94.
Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(10):1922-65.
Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: a systematic review and critical analysis. Ann Intern Med. 2003;139(1):46-50.
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317-70.
Tian S, Chen Y, Zhang Y, Xu X. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2023;37(2):e24823.
Llovet JM. Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound. Clin Gastroenterol Hepatol. 2006;4(1):29-35.
Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55(10):2744-55.
Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol. 2020;20:215.
Gu W, de Lédinghen V, Aubé C, Krag A, Strassburg C, Castéra L, et al. Hepatocellular cancer surveillance in patients with advanced chronic liver disease. NEJM Evid. 2024;3(11). doi:10.1056/EVIDoa2400062.
Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol. 2021;27(2):64-72.
Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S113-9.
Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current imaging diagnosis of hepatocellular carcinoma. Cancers (Basel). 2022;14(16):3997. doi:10.3390/cancers14163997.
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181-223.
Nainggolan FT, Suprianto I, Legiran. Correlation of alpha-fetoprotein levels with three-phase contrast CT-scan finding in hepatocellular carcinoma patients at Dr. Mohammad Hoesin General Hospital Palembang in 2022–2023. Indones J Gastroenterol Hepatol Dig Endosc. 2025;26(2):114-9.
Article Metrics
Abstract View
: 310 times
Download : 471 times
DOI: 10.24871/262202599-100
Refbacks
- There are currently no refbacks.
